Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành hóa học dành cho các bạn yêu hóa học tham khảo đề tài: Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation–a phase I study (MISOT-I) | Popp et al. Journal of Translational Medicine 2011 9 124 http content 9 1 124 JOURNAL OF TRANSLATIONAL MEDICINE PROTOCOL Open Access Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation-a phase I study MISOT-I 1 f 1 f 1 1 1 1 Felix C Popp Barbara Fillenberg Elke Eggenhofer Philipp Renner Johannes Dillmann Volker Benseler Andreas A Schnitzbauer1 James Hutchinson1 Robert Deans2 Deborah Ladenheim2 Cheryl A Graveen2 c I rl Ì vs 7 ft m nr 3 h I I r- p - r-J IX I I r3 IV ỉ I I I I r z t rd I I I I v 4 c rd t A r rd IX AT r I f r I r r 1 I I r I c r- p I i -f-f- 1 -ir rd IV ỉ vr I I rd I 1 r 1 Florian Zeman Michael Koller Martin J Hoogduijn Edward K Geissler Hans J SChlitt and Marc H Dahlke Abstract Background Liver transplantation is the definitive treatment for many end-stage liver diseases. However the lifelong immunosuppression needed to prevent graft rejection causes clinically significant side effects. Cellular immunomodulatory therapies may allow the dose of immunosuppressive drugs to be reduced. In the current protocol we propose to complement immunosuppressive pharmacotherapy with third-party multipotent adult progenitor cells MAPCs a culture-selected population of adult adherent stem cells derived from bone marrow that has been shown to display potent immunomodulatory and regenerative properties. In animal models MAPCs reduce the need for pharmacological immunosuppression after experimental solid organ transplantation and regenerate damaged organs. Methods Patients enrolled in this phase I single-arm single-center safety and feasibility study n 3-24 will receive 2 doses of third-party MAPCs after liver transplantation on days 1 and 3 in addition to a calcineurin-inhibitor-free bottom-up immunosuppressive regimen with basiliximab mycophenolic acid and steroids. The study objective is to evaluate the safety and clinical feasibility of MAPC administration in
